Clinical Trial Update: Umbilical Mesenchymal Stromal Cells as Cellular Immunotherapy for Septic Shock [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating umbilical cord-derived mesenchymal stromal cells as cellular immunotherapy for septic shock, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sepsis
• Septic Shock

Drugs mentioned

• Umbilical cord-derived mesenchymal stromal cells (umbilical cord-derived mesenchymal stromal cells)

Snippet

Sponsor: Ottawa Hospital Research Institute | Conditions: Septic Shock, Sepsis | Phase 2 | Status: RECRUITING